Nicola Redfern

Following 5 years experience working in the gene therapy arena, with a focus on reimbursement and commercialisation, Nicola has set up NJ Redfern Ltd to enable her to consult, coach and collaborate with other organisations, following her departure from bluebird bio in Europe. With a consistent focus over recent decades on rare disease & oncology/ haematology, her primary attention has been on pricing and reimbursement, service delivery and shaping the external environment, alongside building high performing cross functional teams that have enjoyed working together. She has been in the pharmaceutical industry since 1989, joining from Martin House childrens hospice in Yorkshire, and has worked for 10 different companies to date in a diverse range of roles. Nicola has also been an active member of the ABPI – chairing the ATMP working group during 2021; a member of the Value and Access group and also various government affairs and communications initiatives – and worked closely in the last 5 years with the Cell and Gene therapy catapult in the UK.

Nicola is committed to and motivated by patients having a choice and being able to access transformative treatment options quickly once science and innovation reaches a point to positively impact the lives of people living with significant health challenges.

As a member of the board of trustees at Naomi House and Jacks Place – a Hospice for children and young adults near Winchester in Hampshire, UK – and through working alongside multiple patient organisations over her career, she has a strong empathy and understanding of life limiting conditions and their impact on the individual, their families and society as a whole.

She has consistently demonstrated strong leadership capabilities – with a passion for creating and shaping new diverse teams – embedding a positive culture, helping individuals develop, then leading them through defining their strategic focus and driving the initiatives through to completion.